Clinical trials: Hematologic and Lymphocytic Disorder
Myelodysplastic Syndrome
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
Objectives: Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk myelodysplastic syndromes (MDS). Secondary: To evaluate response duration, survival and side effects of the treatment.
- Trial name
- NCT00520468
- Testing
- Erythropoietin, Cyclosporin A, G-CSF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Anemia, Sickle Cell
Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative stress, which will result in a decrease in the…
- Trial name
- NCT01054768
- Testing
- alpha-lipoic acid and acetyl-L-carnitine, Control
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder
Epcoritamab in Previously Treated WM
This study is being done to determine if epcoritamab can be used to treat participants with previously treated Waldenstrom Macroglobulinemia (WM).
- Trial name
- NCT06510491
- Testing
- Epcoritamab
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Gottfried von Keudell, MD PhD
Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML)
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
This is a Phase 1, open label, dose-escalation study to evaluate the safety, expansion, persistence, and preliminary clinical activity of lentivirally transduced autologous T cells expressing anti-CD64 chimeric antigen receptors…
- Conditions
- Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, AML (Acute Myeloid Leukemia)
- Trial name
- NCT07347418
- Testing
- CD64 CAR T Cells
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Colorado, Denver
Chronic Lymphocytic Leukemia
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and mitoxantrone plus rituximab, with the growth factor pegylated filgrastim, will improve the response to treatment…
- Trial name
- NCT00254410
- Testing
- Fludarabine, Cyclophosphamide, Mitoxantrone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00568880
- Testing
- bortezomib, hydroxychloroquine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Multiple Myeloma, Disease of the Marrow
Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions
Developing an MRI protocol at 1.5 T allowing quantification of the hematopoietic, fatty and trabecular moieties of marrow. An ideal protocol would differentiate red marrow from neoplastic cellular infiltration, and detect loss of…
- Conditions
- Multiple Myeloma, Disease of the Marrow, Osteoporosis
- Trial name
- NCT01880762
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Hematologic Malignancy, Pediatric Cancer
Response to Influenza Vaccination in Pediatric Oncology Patients
Influenza infection occurring during oncologic treatment or following hematopoietic cell transplantation (HCT) is associated with increased risk of morbidity in the form of lower respiratory tract infection (LRTI) and mortality…
- Conditions
- Hematologic Malignancy, Pediatric Cancer, Transplant-Related Cancer
- Trial name
- NCT05384288
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Chronic Lymphocytic Leukemia
CFAR Study in Patients With Chronic Lymphocytic Leukemia
Primary Objective: 1. Evaluate the ability of Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) to increase the proportion of patients with <5% CD5/CD19+ cells in bone marrow to 66% following 3 courses of treatment…
- Trial name
- NCT00525603
- Testing
- Cyclophosphamide, Fludarabine, Alemtuzumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
B-Cell Acute Lymphoblastic Leukemia
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of SYNCAR-100 in patients with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
- Trial name
- NCT07429461
- Testing
- SYNCAR-100 Injection
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Zhejiang University
Immune Thrombocytopenia, Blood Coagulation Disorders
The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of combination of Sitagliptin and danazol versus danazol for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).
- Conditions
- Immune Thrombocytopenia, Blood Coagulation Disorders, Thrombocytopenia, Physiological Effects of Drugs
- Trial name
- NCT05353673
- Testing
- Sitagliptin, Danazol
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University People's Hospital
CMV Reactivation, Allogeneic Stem Cell Transplantation
Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation
The investigators will assess whether the infusion of autologous CMV-specific T-cells at the time of CMV reactivation posttransplant will prevent worsening of CMV virus reactivation posttransplant to a level that warrants therapy…
- Conditions
- CMV Reactivation, Allogeneic Stem Cell Transplantation, Autologous CMV Specific CD8+ T Cells
- Trial name
- NCT01326273
- Testing
- Lymphopheresis, CMV specific lymphocyte infusion, Peripheral blood for CMV DNA PCR
- Where
- United Kingdom
- Sponsor
- Imperial College London
Myelodysplastic Syndromes
A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
This study will evaluate a new immunosupressive therapy, Daclizumab, and compare it with antithymocyte globulin (ATG) to treat cytopenia, that is, the deficiency of cellular elements of the blood, in myelodysplastic syndrome…
- Trial name
- NCT00072969
- Testing
- Daclizumab
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)
Comparison of the effects of CYT107 vs Placebo administered by intra-muscular route (IM) at 10μg/kg twice a week for three weeks on immune reconstitution of lymphopenic COVID-19 patients
- Trial name
- ILIAD-7-BRA (NCT04927169)
- Testing
- Interleukin-7
- Where
- 6 sites in Brazil
- Volunteers
- 4 people
- Sponsor
- Revimmune
Chronic Myeloid Leukemia
Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia in Accelerated and Blastic Phase
This is a phase II, multi-center, open-label, non-randomized trial. During Part 1 of the trial, patients will receive once daily oral administration of STI571 at a dose of 600 mg for 24 weeks.
- Trial name
- CML003 (NCT00514969)
- Testing
- Imatinib (STI571)
- Where
- Italy
- Sponsor
- University of Bologna
Neutropenia, Adverse Event
LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy
LEO trial was designed to assess the benefit of administering LifeMel to prevent myelotoxicity in patients affected by solid neoplasm undergoing antiblastic chemotherapy treatment at low to moderate risk of febrile neutropenia.
- Trial name
- LEO (NCT04562922)
- Testing
- Lifemel
- Volunteers
- 39 people
- Sponsor
- VitalMel
Iron-deficiency Anemia
Umbilical Cord Clamping and Infant Iron Status
The aim of the study was to determine whether delayed umbilical cord clamping, as compared to early umbilical cord clamping, improves infant iron status at 6 months of age.
- Trial name
- NCT00298051
- Testing
- Delayed umbilical cord clamping
- Where
- Mexico
- Volunteers
- 476 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
This phase I trial studies the side effects of NY-ESO-1 TCR engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after melphalan conditioning regimen in treating participants with multiple…
- Conditions
- HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NYSCT MM (NCT03506802)
- Testing
- 18F-FHBG, Aldesleukin, Cellular Therapy
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Plasma Cell Dyscrasias
Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders
This study is an open-label, single-arm, dose-escalation and expansion, prospective clinical trial. It enrolls patients with relapsed/refractory plasma cell disorders, administers GPRC5D CAR-T cell therapy, follows up to observe…
- Trial name
- NCT07365059
- Testing
- GPRC5D CAR-T cell intravenous infusion
- Volunteers
- 18 people
- Sponsor
- Qi deng
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
A Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy
This clinical trial determines how well the oncpatient mobile application work in assisting patients undergoing radiation treatment. Radiation therapy can be complex.
- Trial name
- NCT05173961
- Testing
- Internet-Based Intervention, Survey Administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.